GUTS Fractyl health reports positive randomized data from remain-1 midpoint cohort demonstrating durable weight maintenance one year after g
GUTS Fractyl health reports positive randomized data from remain-1 midpoint cohort demonstrating durable weight maintenance one year after glp-1 discontinuation Fractyl health - revita procedure reduces weight regain by 40% versus sham at one year - No device-related serious adverse events reported; teae rates similar between groups - Optimized population maintains 84% of glp-1 weight loss at one year - Topline six-month remain-1 data expected early Q4 2026; FDA submission planned late Q4 2026
GUTS Fractyl health reports positive randomized data from remain-1 midpoint cohort demonstrating durable weight maintenance one year after glp-1 discontinuation Fractyl health - revita procedure reduces weight regain by 40% versus sham at one year - No device-related serious adverse events reported; teae rates similar between groups - Optimized population maintains 84% of glp-1 weight loss at one year - Topline six-month remain-1 data expected early Q4 2026; FDA submission planned late Q4 2026